Becatecarin

Star0

DB06362InvestigationalSmall molecule

Becatecarin is a derivative of rebeccamycin.

Mechanism: Becatecarin is a small molecule, anticancer compound for the treatment of hepatobiliary duct tumors, a rare and aggressive form of cancer with a high medical need and very limited survival. Becatecarin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified), liver cancer, gastric cancer, and leukemia (unspecified).Curator reviewed
Formula / weight: C₃₃H₃₄Cl₂N₄O₇ · 669.56 g/mol (avg)
Also known as: 6-(2-(DIETHYLAMINO)ETHYL)-REBECCAMYCIN · DEAE-rebeccamycin
Code names: BMS-181176 · BMY-27557 · NSC-655649 · XL-119

Resolves to

Compound

UNIIA60X6MBU6GCAS119673-08-4ChEMBLCHEMBL2107313

Structure

InChIKeyJSKFWUPVIZYJMR-UDOAKELVSA-NSMILESCCN(CC)CCN1C(=O)C2=C(C1=O)C1=C(N([C@@H]3O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]3O)C3=C(Cl)C=CC=C13)C1=C2C2=C(N1)C(Cl)=CC=C2

Targets

P11387TOP1P11388TOP2AQ02880TOP2B

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Becatecarin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account